Bionure, a Barcelona, Spain-based clinical stage R&D company specialized in the treatment of neurodegenerative diseases, has appointed Lucia Septien as chief medical officer (CMO).

Septien joins Bionure from DBV Technologies where she also held the CMO position. Prior to that, she worked as a clinical doctor in neurology and psychiatry and then held diverse roles at major pharmaceutical companies, including Pfizer, Wyeth, GSK, Servier and Ipsen.

"We warmly welcome Lucia to Bionure. With her sensitivity for patients, her solid experience in CNS drug development and her leadership skills, she will strengthen our team," said Laurent Nguyen, CEO of Bionure. “We are convinced of her ability to successfully implement our neuroprotection projects.”